Dr. Peter Stirling, PhD, Associate Professor at the University of British Columbia and Senior Scientist at the Terry Fox Laboratory, BC Cancer is pursuing research that targets aggressive and notoriously treatment-resistant glioblastoma (GBM) tumours. The research aims to develop bi-functional FEN1 inhibitors that promise to enhance the treatment of glioblastomas by inducing synthetic lethality and stimulating the immune response within tumors.
This project, which Brain Cancer Canada is pleased to support, benefits from the collaboration with experts like Dr. Philip Hieter and Dr. Sheila Singh, who bring specialized knowledge in molecular genetics and clinical practice, respectively. Dr. Stirling shared his vision for the project, stating, "Our goal is to transform the treatment landscape for glioblastoma patients by developing therapies that are not only more effective but also harness the body's own immune system to fight cancer. This could significantly improve outcomes for patients facing this challenging diagnosis."